Tune Therapeutics

Seattle, Washington, USA and Durham, North Carolina, USA

Tune Therapeutics develops TEMPO, an epigenomic platform that fine-tunes gene activity without altering DNA. It is developing therapies for chronic hepatitis B, rare single-gene disorders and other conditions.

Facts

HQ
Seattle, Washington, USA and Durham, North Carolina, USA
Sectors
Biotechnology, Therapeutics, Epigenomics
Stage
Series B
Members see funding amounts.
.

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about Tune Therapeutics

See all 6

Blue Origin's New Glenn Rocket Achieves First Orbital Launch Amid Schedule Hiccups; Microsoft Creates New AI Division Led by Ex-Facebook Chief; Truveta Raises $320M for Genome Initiative

Jeff Bezos' Blue Origin faced multiple scheduling changes before successfully launching its heavy-lift New Glenn rocket to orbit for the first time. Additionally, Microsoft established a new AI division led by a former Facebook engineering chief, and Seattle's Truveta secured $320 million to start a large genome project.

Questions about Tune Therapeutics

What is Tune Therapeutics?

Seattle, Washington, USA and Durham, North Carolina, USA

Who invested in Tune Therapeutics, and how much has it raised?

Members of Seattle Flow see Tune Therapeutics' funding rounds, amounts and investors on its Funding tab. Joining is free.

Where is Tune Therapeutics based?

Tune Therapeutics is headquartered in Seattle, Washington, USA and Durham, North Carolina, USA.